adrenocortical carcinoma
Disease Detail

Request Content

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

ID DOID:3948
Name adrenocortical carcinoma
Definition An adrenal cortex cancer that forms in the outer layer of tissue of the adrenal gland and that has_material_basis_in abnormally proliferating cells derives_from epithelial cells.
Source DiseaseOntology.org
Alt Ids
Path disease disease of cellular proliferation cancer organ system cancer endocrine gland cancer adrenal gland cancer adrenal cortex cancer adrenocortical carcinoma

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Molecular Profile Therapy Indication/Tumor Type Response Type Profile Response Detail
FGFR1 amp Derazantinib adrenocortical carcinoma sensitive detail...
TP53 mutant N/A adrenocortical carcinoma not applicable detail...
MLH1 mutant N/A adrenocortical carcinoma not applicable detail...
MSH6 mutant N/A adrenocortical carcinoma not applicable detail...
APC mutant N/A adrenocortical carcinoma not applicable detail...
Clinical Trial Phase Therapies Title Recruitment Status Covered Countries Other Countries
NCT01396408 Phase II Temsirolimus Sunitinib A Phase II Study of Sunitinib or Temsirolimus in Patients With Advanced Rare Tumours Active, not recruiting CAN 0
NCT01898715 Phase I ATR-101 Phase 1 Study of ATR-101 in Subjects With Advanced Adrenocortical Carcinoma Completed USA | DEU 0
NCT02720484 Phase II Nivolumab Nivolumab in Treating Patients With Metastatic Adrenocortical Cancer Terminated USA 0
NCT02721732 Phase II Pembrolizumab Study for the Evaluation of Efficacy of Pembrolizumab (MK-3475) in Patients With Rare Tumors Active, not recruiting USA 0
NCT03333616 Phase II Ipilimumab + Nivolumab Nivolumab Combined With Ipilimumab for Patients With Advanced Rare Genitourinary Tumors Active, not recruiting USA 0
NCT03370718 Phase II Cabozantinib Cabozantinib in Unresectable/Metastatic Adrenocortical Carcinoma Completed USA 0
NCT03612232 Phase II Cabozantinib Cabozantinib in Advanced Adrenocortical Carcinoma (CaboACC) Active, not recruiting DEU 0
NCT03746431 Phase Ib/II 225Ac-FPI-1434 A Phase 1 Study of [225Ac]-FPI-1434 Injection Active, not recruiting USA | CAN | AUS 0
NCT04187404 Phase Ib/II EO2401 + Nivolumab A Novel Therapeutic Vaccine (EO2401) in Metastatic Adrenocortical Carcinoma, or Malignant Pheochromocytoma/Paraganglioma (Spencer) Terminated USA | SWE | NLD | ITA | FRA | ESP | DNK | DEU 0
NCT04373265 Phase I Pembrolizumab + Relacorilant Study of Relacorilant in Combination With Pembrolizumab for Patients With Adrenocortical Carcinoma With Excess Glucocorticoid Production Completed USA 0
NCT04400474 Phase II Atezolizumab + Cabozantinib Trial of Cabozantinib Plus Atezolizumab in Advanced and Progressive Neoplasms of the Endocrine System. The CABATEN Study (CABATEN) Completed ESP 0
NCT04544995 Phase I Dostarlimab-gxly + Niraparib Dose Escalation and Cohort Expansion Study of Niraparib and Dostarlimab in Pediatric Participants With Solid Tumors Terminated GBR | FRA | ESP | CZE 0
NCT05563467 Phase II Pembrolizumab Pembrolizumab in the Treatment of Advanced, Progressive Adrenocortical Carcinoma. (PEMBR-01) Recruiting POL 0
NCT05634577 Phase II Mitotane + Pembrolizumab A Phase II Study to Evaluate the Efficacy and Safety of Pembrolizumab in Combination With Mitotane in Patients With Advanced Adrenocortical Carcinoma Terminated USA 0
NCT05841563 Phase I PM54 Clinical Trial of PM54 in Advanced Solid Tumors Patients. Recruiting USA | ESP | BEL 0
NCT06006013 Phase II Atezolizumab + Cabozantinib Cabozantinib in Combination With Atezolizumab for the Treatment of Patients With Locally Advanced, Metastatic, or Unresectable Adrenal Cortical Cancer Active, not recruiting USA 0
NCT06041516 Phase I ADCT-701 Antibody Drug Conjugate ADCT-701 in Neuroendocrine Tumors and Carcinomas Recruiting USA 0
NCT06066333 Phase II Pembrolizumab Study of Radiotherapy and Pembrolizumab in People With Adrenocortical Carcinoma Recruiting USA 0
NCT06333314 Phase II Dostarlimab-gxly Fluorouracil + Irinotecan + Leucovorin + Oxaliplatin Doxorubicin Gemcitabine Gemcitabine + Nab-paclitaxel Doxorubicin + Trabectedin Fluorouracil + Leucovorin + Oxaliplatin Cisplatin + Etoposide Cisplatin + Gemcitabine Cisplatin + Doxorubicin + Etoposide Capecitabine + Oxaliplatin Doxorubicin + Ifosfamide Carboplatin + Etoposide Carboplatin + Paclitaxel Docetaxel + Fluorouracil + Leucovorin + Oxaliplatin Mitotane Dostarlimab for Locally Advanced or Metastatic Cancer (Non-colorectal/Non-endometrial) With Tumor dMMR/MSI (Pan-MSI-ACSE) Recruiting FRA 0
NCT06900595 Phase II Cabozantinib Cabozantinib + Cemiplimab Testing the Addition of an Anti-Cancer Drug, Cabozantinib to the Immunotherapy Drug Cemiplimab (REGN2810), in Adolescents and Adults With Advanced Adrenocortical Cancer Recruiting USA 0
NCT07085572 Phase II Cemiplimab Cemiplimab as Maintenance Treatment for Advanced Adrenocortical Cancer (INTERVAL) Recruiting ITA 0
NCT07189403 Phase I DS9051b A Study of DS9051b in Participants With Advanced or Metastatic Adrenocortical Carcinoma and Metastatic Castration-resistant Prostate Cancer Recruiting USA | GBR | FRA 0